Neurotech Receives $4.73m R&D Refund to Advance Autism and PANDAS Treatments
Neurotech International has received a $4.73 million R&D tax incentive refund, reinforcing its clinical development efforts in paediatric neurological disorders. The funds will support ongoing trials and working capital needs.
- Received $4.73 million R&D tax incentive refund for FY2025
- Funds to advance clinical trials targeting paediatric neurological disorders
- Focus on Autism Spectrum Disorder, PANDAS/PANS, Rett Syndrome, and cerebral palsy
- Clinical-stage biopharmaceutical company with promising trial results
- Refund supports both pipeline development and working capital
Neurotech’s Financial Boost
Neurotech International Limited (ASX, NTI), a clinical-stage biopharmaceutical company specialising in paediatric neurological disorders, has announced the receipt of a $4.73 million research and development (R&D) tax incentive refund for the financial year ended 30 June 2025. This significant refund, provided under the Australian Government’s R&D tax incentive scheme, offers a refundable tax offset of up to 48.5% for eligible activities.
The injection of funds comes at a critical time as Neurotech continues to advance its clinical pipeline, which includes treatments for Autism Spectrum Disorder (ASD), Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS/PANS), Rett Syndrome, and spastic cerebral palsy.
Clinical Progress and Pipeline Potential
Neurotech’s lead candidate, NTI164, is a broad-spectrum oral cannabinoid therapy that has shown promising results in multiple clinical trials. The company recently completed a Phase II/III randomised, double-blind, placebo-controlled trial in ASD, reporting statistically significant and clinically meaningful benefits alongside an excellent safety profile. Earlier Phase I/II trials also demonstrated positive outcomes in ASD and PANDAS/PANS, as well as Rett Syndrome.
Additionally, Neurotech has secured human ethics committee clearance to initiate a Phase I/II clinical trial targeting spastic cerebral palsy, marking another important step in expanding its therapeutic reach within paediatric neurology.
Strategic Use of Funds
The $4.73 million refund will be strategically deployed to accelerate clinical development activities and support working capital requirements. While the announcement does not detail the precise allocation of funds across individual projects, the financial boost is expected to underpin ongoing trials and potentially expedite regulatory milestones.
For investors and stakeholders, this refund not only validates Neurotech’s commitment to innovation in a challenging therapeutic area but also strengthens its financial position amid the costly and complex drug development process.
Bottom Line?
Neurotech’s latest R&D refund underscores its growing momentum in paediatric neurology, setting the stage for upcoming clinical milestones.
Questions in the middle?
- How will Neurotech allocate the R&D refund across its multiple clinical programs?
- What are the anticipated timelines for data readouts from the spastic cerebral palsy trial?
- Could this financial boost influence Neurotech’s partnerships or funding strategies moving forward?
